株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の医薬品卸売および流通市場の予測:ブランド/ジェネリック医薬品流通企業の見通し - 主要企業のプロファイル、業績および収益予測

Pharma Wholesale and Distribution Market Forecasts 2016-2026: Prospects for Companies in Original-Branded and Generic Drug Distribution, Profiles, Performance and Revenue Forecasting of Leading Wholesalers in the US, Europe, Japan and China

発行 Visiongain Ltd 商品コード 247784
出版日 ページ情報 英文 272 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=147.86円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
世界の医薬品卸売および流通市場の予測:ブランド/ジェネリック医薬品流通企業の見通し - 主要企業のプロファイル、業績および収益予測 Pharma Wholesale and Distribution Market Forecasts 2016-2026: Prospects for Companies in Original-Branded and Generic Drug Distribution, Profiles, Performance and Revenue Forecasting of Leading Wholesalers in the US, Europe, Japan and China
出版日: 2016年09月15日 ページ情報: 英文 272 Pages
概要

当レポートでは、医薬品の卸売および流通産業に注目し、その市場環境を探るとともに、将来の全世界、地域・企業・分野・国別の事業収益やトレンドを探る市場調査データをまとめています。

第1章 レポート概要

第2章 市場イントロダクション

  • 医薬品卸売業の役割
  • 流通チェーン
  • 収益および利益を生み出す

第3章 世界の医薬品卸売および流通市場

  • 世界市場
  • 世界市場予測
  • ブランドおよびジェネリック薬品

第4章 医薬品卸売および流通産業:主要国市場

  • 主要国市場:2015年は米国が優勢
  • 主要国市場の将来:米国が市場をリードし続けるのか?
  • 米国の医薬品卸売および流通市場
    • 財政管理法と米国市場におけるその効果
    • 州ごとに異なる偽造薬防止法
    • 診療ごと個別支払い額の増加
    • 米国市場予測
  • 欧州主要市場(EU5ヵ国)
    • 米国と欧州の違い
    • 公的医療保険と償還制度
    • 主要EU5ヵ国:市場予測
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 英国
  • 日本
    • 薬剤価格設定と成果報酬
    • 市場予測
  • 中国
    • 有力企業
    • 市場予測
  • ブラジル
    • 薬価管理
    • 有力企業
    • 市場予測
  • インド
    • 市場予測
  • ロシア
    • 薬価管理
    • 市場動向
    • 市場予測
  • 結びのコメント

第5章 有力医薬品卸売および流通企業

  • 主要企業
  • 「収益」対「利益」
  • 有力企業:グループ連結予測
  • McKesson
  • Cardinal Health
  • AmerisourceBergen
  • Walgreens Boots Alliance
  • MEDIPAL HOLDINGS CORPORATION
  • The PHOENIX Group
  • SINOPHARM
  • Alfresa Holdings
  • スズケン
  • Shanghai Pharmaceuticals Holding

第6章 定性的市場分析

  • 強みと弱み
  • 機会と脅威
  • 市場への社会・技術・経済・政治的な影響因子(STEP分析)

第7章 調査インタビュー

第8章 調査から得られた結論

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0141

Title:
PHARMA WHOLESALE AND DISTRIBUTION MARKET FORECASTS 2016-2026
Prospects for Companies in Original-Branded and Generic Drug Distribution; Profiles, Performance and Revenue Forecasting of Leading Wholesalers in the US, Europe, Japan and China, including McKesson, Cardinal Health, AmerisourceBergen, Walgreens Boots Alliance, MEDIPAL, PHOENIX Group, SINOPHARM and Suzuken.

Pharma Wholesaling and Distribution - Analysis of Companies, Trends and Future Revenues to Benefit Your Influence

What does the future hold for drug wholesale and distribution (W&D) services? Discover revenue predictions there to 2026. And explore trends in those services and technologies, assessing prospects and finding opportunities to benefit your work and authority.

In visiongain's new report you gain revenue forecasts at overall world market, submarket, company and national level. There you assess potentials for expanding revenues. See where that industry's best prospects lie.

Please read on to explore activities of distributors and wholesalers of pharmaceuticals, discovering what that business's future could be worth.

Forecasts and other analysis to benefit your knowledge of medical distribution systems

Is finding pharma wholesale and distribution information a challenge? Avoid falling behind in knowledge on the supply of medicines. With our data, help your research, analyses and decisions. Also save time and benefit your reputation for commercial insight.

Besides revenue forecasting, our new investigation shows historical data, growth rates and market shares. That industry changes in 2016 through mergers and acquisitions. In our study discover what is happening, helping you stay ahead.

There you find original quantitative and qualitative analyses, exploring business outlooks and developments. In our 272 page study you gain 83 tables, 98 charts and a research interview.

Discover where revenues can increase most. In the following sections you see how our new study benefits your knowledge on the supply chain for human medicines.

Prospects for that world market and submarkets - discover what revenues are possible

Our new report shows revenue to 2026 for the overall world market. It also gives you forecasts for three submarkets in the distributing and wholesaling of medicines:

  • Original-branded pharmaceuticals - small molecules and biological drugs
  • Generic prescription medicines - generics
  • Other products related to pharmaceutical supply.

Discover pharma distribution chain revenues. How will that wholesaling and distributing market grow? Which parts will prosper most, and why? With our data you assess potential sales and revenue growth. See what is possible from 2016.

In our study you also discover geographical revenue predictions.

Sales potentials for medical wholesaling and distributing in leading countries

Developments worldwide expand the pharma W&D market, especially rising demand for medicines in fast-emerging countries. China, India, Russia and Brazil underpin revenue growth. Discover how domestic and international suppliers expand business.

In developed and developing regions opportunities for drug wholesalers and other medical suppliers will occur from 2016. Pharmacies also stand to gain. See where, why and how, discovering what is possible.

Our report shows you individual revenue forecasts to 2026 for 11 national markets:

  • United States
  • Japan
  • Germany, France, United Kingdom, Italy and Spain (EU5)
  • Brazil, Russia, India and China (BRIC).

There you discover progress and outlooks. You assess the W&D industry's future, seeing developments and finding their meaning.

Forecasting and other analyses for leading pharma supply chain intermediaries

How will prominent W&D companies perform to 2026? Our work shows you individual revenue forecasts for 10 leading pharma wholesalers and distributors:

  • McKesson
  • Cardinal Health
  • AmerisourceBergen
  • Walgreens Boots Alliance
  • MEDIPAL HOLDINGS
  • The PHOENIX Group
  • SINOPHARM
  • Alfresa Holdings
  • Suzuken
  • Shanghai Pharmaceutical Holdings.

With our sales predictions you assess organisations, seeing activities, results, changes and outlooks. You find what is happening, exploring trends, competition, challenges and opportunities.

That way you investigate the pharma W&D industry's prospects, discovering progress and finding what it means. Our study explains the issues affecting that industry's present and future.

Forces and changes affecting the supply of medicines through distribution networks

Our report explains issues, events and shifts affecting that industry and market from 2016, including these influences:

  • Roles of pharmaceutical wholesalers - activities, changes and prospects
  • Revenues, costs and profits - find results, opportunities and sales potentials
  • Direct-to-pharmacy (DTP) activities - assess how those developments affect suppliers, clients and the W&D market
  • Full-line wholesalers (FLWs), short-line wholesalers (SLWs) and the drug distribution chain, including logistical service providers
  • Technologies and services - progress in supplying pharmacies, clinics and hospitals, serving healthcare professionals, governments, payers and patients
  • Forward buying, fee-for-service systems and the rise of retail pharmacies.

Our investigation also discusses other aspects of that industry, including these forces:

  • Alliance Boots merging with Walgreens, McKesson's acquisition of Celesio and other consolidation - explore deals changing that industry
  • Parallel trade - activities, policies, challenges and effects
  • Inventory management agreements, clawback, reimbursement and discounts
  • Rise of specialty medicines, including biologics, vaccines and biosimilars - opportunities for intermediaries, including cold chain distribution networks
  • Actions against drug counterfeiting - security of pharmaceutical supply chains
  • Changes to regulations and healthcare budgets - policies affecting trade.

That way you assess technological, economic, social and political questions, exploring news and outlooks for the medical supply chain. You also analyse that industry's strengths, weaknesses, opportunities and threats. See what the future holds.

Value of the overall pharma W&D market in 2020 - what revenue is possible?

Visiongain forecasts that the overall pharmaceutical wholesale and distribution industry will achieve revenue of $1,357 billion worldwide in 2020. That market will rise further - see what gains are possible.

Wholesaling and distributing services will experience steady revenue growth from 2016 to 2026, adapting to driving and restraining forces - changes, opportunities and threats. Find how high that industry's turnover can go, also exploring what influences its revenues and profits.

So discover, with our data, revenue streams and opportunities for intermediaries in the pharma supply chain. There you explore established and rising companies. Their market holds great potential from 2016 for investments, progress and expansion.

6 main ways Pharma Wholesale and Distribution Market Forecasts 2016-2026 helps

In our new analysis you gain the following knowledge to benefit your analyses, plans, presentations and authority:

  • World pharma W&D revenue to 2026 - discover that industry's overall sales potential from 2016
  • 3 world-level submarkets' revenues to 2026 - investigate potentials, finding the most promising segments for developments, investments and sales
  • 10 top companies' revenues to 2026 - discover forecasts for leading players, seeing how they develop their businesses, compete and succeed
  • 11 national market forecasts to 2026 in the Americas, Europe and Asia - explore top countries for revenues, demand and potential sales expansion
  • Activities of leading organisations - analyse participants' financial results, strategies, capacities, partnerships, mergers and acquisitions
  • Competition and opportunities - explore what shapes that industry's future, assessing prospects for sustaining and developing business.

That report, by visiongain's in-house analysts in the UK, gives knowledge with the purpose of saving you effort and time, making your work easier and more likely to succeed. You gain analysis leading companies depend on.

Data found nowhere else - benefit your research, decisions, plans and influence

Our investigation gives independent analysis. There you receive discussions and predictions found only in our report, seeing where prospects are most rewarding.

With our study you are less likely to fall behind in knowledge or miss opportunity. Discover there how you could benefit your research, analyses, plans and decisions, also saving time and getting recognition for commercial insight.

Our analysis costs only a tiny fraction of potential profits from your exploring and harnessing the pharma W&D market. Assess its changes and growth potentials.

Forecasts for pharmaceutical supply - stay ahead by trying our analysis now

Our new study is for everyone analysing the supply of human medicines. In that work you explore results, trends, opportunities and revenue predictions, seeing what is possible. Avoid missing out. Stay ahead by getting our report here now.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Global Pharma Wholesale and Distribution Industry and Market Overview
  • 1.2. Pharma Wholesale and Distribution Industry Structure
  • 1.3. Benefits of This Report
  • 1.4. How This Report Delivers
  • 1.5. Questions Answered by This Analytical Report
  • 1.6. Who is This Report For?
  • 1.7. Methodology
  • 1.8. Frequently Asked Questions (FAQ)
  • 1.9. Associated Visiongain Reports
  • 1.10. About Visiongain

2. Introduction to Pharma Wholesale and Distribution

  • 2.1. The Role of Pharmaceutical Wholesalers: The Middlemen of the Pharmaceutical Industry
    • 2.1.1. Full-Line Wholesalers (FLWs)
    • 2.1.2. Short-Line Wholesalers (SLWs)
  • 2.2. The Chain of Distribution: Wholesalers vs. Logistic Service Providers
    • 2.2.1. Secondary Wholesalers
    • 2.2.2. Direct-to-Pharmacy (DTP) Distribution is Becoming More Prevalent
    • 2.2.3. Major Wholesalers: Distribution of a Large Number of Products to Generate High Profits
    • 2.2.4. Distribution from Large to Small Wholesalers: A Lengthy Distribution Chain
    • 2.2.5. Pharmacy Benefit Managers
  • 2.3. Generative Revenue and Profit
    • 2.3.1. Forward Buying to Avoid Price Increases
    • 2.3.2. Fee-for-Service: A Clear Pricing Structure
      • 2.3.2.1. Inventory Management Agreements
    • 2.3.3. Discounts: Incentives for Prompt Payment or Bulk Purchases
    • 2.3.4. Reimbursement and Wholesalers
    • 2.3.5. Clawback: The Recovery of Reimbursement Costs by Governments
    • 2.3.6. Parallel Trade: Different Attitudes in Europe and the US

3. The World Pharmaceutical Wholesale and Distribution Market: 2015-2026

  • 3.1. The World Pharmaceutical Wholesale and Distribution Market in 2015, Restricted by Government Price Reductions and Generic Substitution
  • 3.2. The Pharmaceutical Wholesale and Distribution Industry: World Market Forecast, 2015-2026
  • 3.3. Branded and Generic Drugs: Revenue vs. Profit, 2015-2026
    • 3.3.1. Branded and Generic Drugs: Revenue Generation, 2015
    • 3.3.2. Branded Drugs: Revenue Forecast, 2015-2026
    • 3.3.3. Generic Drugs: Revenue Forecast, 2015-2026

4. Pharmaceutical Wholesale and Distribution Industry: Leading National Markets, 2015-2026

  • 4.1. The Leading National Markets: the US Dominates in 2015
  • 4.2. The Future of the Leading National Markets: Will the US Continue to Dominate the Market?
  • 4.3. The US Pharma Wholesale and Distribution Market
    • 4.3.1. The Budget Control Act and its Effect on the US Wholesale and Distribution Industry
    • 4.3.2. Legislation to Prevent Counterfeit Drugs Can Differ Between States
    • 4.3.3. An Increase in Fee-For-Service Activity
    • 4.3.4. Pharma Wholesale and Distribution Market in the US: Market Forecast, 2015-2026
  • 4.4. The Leading European (EU5) Pharma Wholesale and Distribution Markets
    • 4.4.1. The Difference Between the US and European Markets
    • 4.4.2. State-Funded Healthcare and Reimbursement
    • 4.4.3. EU5: Market Forecast, 2015-2026
    • 4.4.4. Germany: Pharma Wholesale and Distribution Market, 2015
      • 4.4.4.1. Healthcare Reform
      • 4.4.4.2. Germany: Reform of AMNOG Pharmaceutical Rebate Law
      • 4.4.4.3. Germany Pharma Wholesale and Distribution Market Forecast, 2015-2026
    • 4.4.5. France: Pharma Wholesale and Distribution Market, 2015
      • 4.4.5.1. France: Social Security Finance Bill 2015
      • 4.4.5.2. France: Pharma Wholesale and Distribution Market Forecast, 2015-2026
    • 4.4.6. Italy: Pharma Wholesale and Distribution Market, 2015
      • 4.4.6.1. Italy: Pharma Wholesale and Distribution Market Forecast, 2015-2026
    • 4.4.7. Spain: Pharma Wholesale and Distribution Market, 2015
      • 4.4.7.1. Spain: Pharma Wholesale and Distribution Market Forecast, 2015-2026
    • 4.4.8. UK: Pharma Wholesale and Distribution Market, 2015
      • 4.4.8.1. Price Cuts in the UK
      • 4.4.8.2. UK: Pharma Wholesale and Distribution Market Forecast, 2015-2026
  • 4.5. Japan: Pharma Wholesale and Distribution Market, 2015
    • 4.5.1. Drug Pricing and Performing Fees in Japan
    • 4.5.2. Japan: Pharma Wholesale and Distribution Market Forecast, 2015-2026
  • 4.6. China: Pharma Wholesale and Distribution Market, 2015
    • 4.6.1. China: Leading Pharma Wholesale and Distribution Companies, 2015
    • 4.6.2. China: Pharma Wholesale and Distribution Market Forecast, 2015-2026
  • 4.7. Brazil: Pharma and Wholesale Distribution Market, 2015
    • 4.7.1. Drug Price Controls in Brazil
    • 4.7.2. Brazil: Leading Pharma Wholesale and Distribution Companies, 2015
    • 4.7.3. Brazil: Pharma Wholesale and Distribution Market Forecast, 2015-2026
  • 4.8. India: Pharma Wholesale and Distribution Market, 2015
    • 4.8.1. India: Pharma Wholesale and Distribution Market Forecast, 2015-2026
  • 4.9. Russia: Pharma Wholesale and Distribution Market, 2015
    • 4.9.1. Drug Pricing Controls in Russia
    • 4.9.2. Market Trends in Russia
    • 4.9.3. Russia: Pharma Wholesale and Distribution Market Forecast, 2015-2026
  • 4.10. Conclusion

5. Leading Pharma Wholesalers and Distributors in 2016: Current and Future Performance

  • 5.1. The Leading Pharma Wholesalers and Distribution Companies in 2015
  • 5.2. Revenue vs. Profit
  • 5.3. Leading Pharma Wholesale and Distribution Companies: Grouped Forecasts, 2015-2026
  • 5.4. McKesson: The Oldest and Largest Healthcare Services Company in the US
    • 5.4.1. McKesson: Historical Performance, 2010-2015
    • 5.4.2. Future Strategies: Consummate Acquisitions to Complement Existing Business or Expand Businesses
    • 5.4.3. McKesson: Revenue Forecast, 2015-2026
  • 5.5. Cardinal Health: The World's Third Largest Pharma Wholesaler
    • 5.5.1. Cardinal Health: Historical Performance, 2010-2015
    • 5.5.2. Will CVS Joint Venture and Acquisitions Stimulate Future Growth?
    • 5.5.3. Cardinal Health: Revenue Forecast, 2015-2026
  • 5.6. AmerisourceBergen: Second Largest Global Pharma Wholesaler and Distributor
    • 5.6.1. AmerisourceBergen: Historical Performance, 2015
    • 5.6.2. Will Contracts with Walgreens and Alliance Boots Drive Future Growth?
    • 5.6.3. AmerisourceBergen: Revenue Forecast, 2015-2026
  • 5.7. Walgreens Boots Alliance: The Largest Drugstore Chain in the US and Global Wholesale and Distribution Network
    • 5.7.1. Walgreens Boots Alliance: Historical Performance, 2011-2015
    • 5.7.2. Acquisitions and Future Strategies of Walgreens Boots Alliance
    • 5.7.3. Walgreens Boots Alliance: Revenue Forecast, 2015-2026
  • 5.8. MEDIPAL HOLDINGS CORPORATION: Japan's Leading Pharmaceutical Wholesaler
    • 5.8.1. MEDIPAL HOLDINGS CORPORATION: Historical Performance, 2011-2015
    • 5.8.2. Future Strategies of MEDIPAL HOLDINGS CORPORATION: Revised Business Portfolio with Diverse Sources of Earnings
    • 5.8.3. MEDIPAL HOLDINGS CORPORATION: Revenue Forecast, 2015-2026
  • 5.9. Phoenix Group: Biggest European Wholesalers
    • 5.9.1. The PHOENIX Group: Historical Performance, 2011-2015
    • 5.9.2. Future Strategies of the PHOENIX Group: Selective Acquisition
    • 5.9.3. The PHOENIX Group: Revenue Forecast, 2015-2026
  • 5.10. SINOPHARM: The Leading Pharmaceutical Wholesaler and Distributor in China
    • 5.10.1. SINOPHARM: Historical Performance, 2011-2015
    • 5.10.2. Future Strategies of SINOPHARM: Provide Comprehensive Services and Wider Business Coverage
    • 5.10.3. SINOPHARM: Revenue Forecast, 2015-2026
  • 5.11. Alfresa Holdings: Second Largest Pharmaceutical Wholesaler and Distributor in Japan
    • 5.11.1. Alfresa Holdings: Historical Performance, 2011-2015
    • 5.11.2. Future Strategy of Alfresa Holdings: To Focus on Expanding Business Fields and Increasing Footprint
    • 5.11.3. Alfresa Holdings: Revenue Forecast, 2015-2026
  • 5.12. SUZUKEN CO., LTD: The First Nationwide Wholesaler of Japan
    • 5.12.1. SUZUKEN CO. LTD: Historical Performance, 2011-2015
    • 5.12.2. Future Strategies of SUZUKEN CO., LTD: Five Growth Initiatives and Special Focus on Diabetes Field
    • 5.12.3. SUZUKEN CO., LTD: Revenue Forecast, 2015-2026
  • 5.13. Shanghai Pharmaceuticals Holding: China's Second Largest Wholesaler
    • 5.13.1. Shanghai Pharmaceuticals Holding: Historical Performance, 2011-2015
    • 5.13.2. Future Strategies of Shanghai Pharma: Expansion of Three Leading Regions in China
    • 5.13.3. Shanghai Pharma: Revenue Forecast, 2015-2026

6. Qualitative Analysis of the Pharma Wholesale and Distribution Market

  • 6.1. The Strengths and Weaknesses of the Pharma Wholesale and Distribution Market, 2016
    • 6.1.1. The Insatiable Demand for Drugs: A Recession Proof Industry?
    • 6.1.2. Wholesalers Do More than Deliver Drugs
      • 6.1.2.1. Pre-Wholesaling: More Prevalent in Europe
      • 6.1.2.2. Through Pre-Financing, Full-Line Wholesalers Finance the Entire Medicines Market
    • 6.1.3. Large Companies Dominate the Market
    • 6.1.4. Despite High Revenues, Profit Margins Are Low
    • 6.1.5. Government-Induced Drug Price Pressures Restrict Profits
    • 6.1.6. The Problem of Counterfeit Drugs
  • 6.2. The Opportunities and Threats of the Pharma Wholesale and Distribution Market, 2015-2026
    • 6.2.1. The Demand for Pharmaceuticals is Increasing
    • 6.2.2. The Increasing Use of Specialty Drugs Will Drive Growth
    • 6.2.3. The Increasing Use of Generic Drugs Will Limit Revenue, But Drive Profit Generation
    • 6.2.4. The Promotion of Drug Therapy in the US
    • 6.2.5. Globalisation: The Major National Markets are Dominated by Few Companies
    • 6.2.6. Increased Adoption of the DTP Distribution Model
      • 6.2.6.1. DTP in Europe: The First Place the Scheme Has Taken Hold
      • 6.2.6.2. DTP in the UK Since 1991
      • 6.2.6.3. DTP in Poland: The Second European Country To Adopt the DTP Model
      • 6.2.6.4. Further Expansion of the DTP Model
    • 6.2.7. The Threat of Healthcare Budget Cuts
      • 6.2.7.1. Healthcare Budget Cuts in Germany
      • 6.2.7.2. Healthcare Budget Cuts in France
      • 6.2.7.3. Healthcare Budget Cuts in Italy
      • 6.2.7.4. Healthcare Budget Cuts in Spain
      • 6.2.7.5. Healthcare Budget Cuts in the UK
    • 6.2.8. Do Large Pharmacy Chains Pose a Threat?
      • 6.2.8.1. Case Study: Walmart and the $4 Prescription Scheme
      • 6.2.8.2. Vertical Integration of Wholesalers: A Response to the Threat of Pharmacy Chains
    • 6.2.9. Does the Diversion and Re-Importation of Medicines Pose a Threat to the Industry?
    • 6.2.10. The Threat of Industry Consolidation
  • 6.3. Social, Technological, Economical and Political Factors Influencing the Market, 2015-2026(STEP Analysis)
    • 6.3.1. Political Factor: The Impact of Recent Regulatory Changes in the EU
    • 6.3.2. Political Factor: Combating Counterfeit Medicines
      • 6.3.2.1. The US and E-Pedigree: Becoming Law in California
      • 6.3.2.2. European Pedigree Legislation
      • 6.3.2.3. Anti-Counterfeiting Strategies in Other Markets: The Chinese Government is Attempting to Address the Challenge
      • 6.3.2.4. Serialisation for Wholesalers: Opportunity or a Challenge?

7. Research Interview

  • 7.1. Interview with Mr Chris Frost, Sales Director of AAH Pharmaceuticals Ltd., (Celesio UK), Coventry
    • 7.1.1. Current Status and Evolution of Pharma Wholesale and Distribution Market, UK
    • 7.1.2. Driving Factors of the Pharma Wholesale and Distribution Market in the UK?
    • 7.1.3. Future of the UK Pharma Wholesale and Distribution Market
    • 7.1.4. Celesio UK Accounted for More than 60% of the Group's Total Retail Pharmacy Business in 2013
    • 7.1.5. The Outcome of McKesson's Acquisition of Celesio AG
    • 7.1.6. Prominent Business Segments of Celesio AG in the Future

8. Conclusions

  • 8.1. The Future of the Pharma Wholesale and Distribution Market
  • 8.2. The Leading National Pharma Wholesale and Distribution Markets
  • 8.3. The Leading Companies in the Pharma Wholesale and Distribution Industry
  • 8.4. Trends in the Pharma Wholesale and Distribution Industry
    • 8.4.1. Generics Will Threaten Revenue
    • 8.4.2. Manufacturers Will Deliver More Drugs Directly
    • 8.4.3. There Will Be Greater Demand for Specialty Medicines
    • 8.4.4. Consolidation Will Drive Growth
    • 8.4.5. Anti-Counterfeiting Demands Will Add to Wholesalers' Costs

List of Tables

  • Table 1.1: (Sample) The Global Pharma Wholesale and Distribution Industry and Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Top Company, 2015-2026
  • Table 1.2: Foreign Currency Exchange Rates to $US, 2015
  • Table 2.1: Use of DTP Model in the UK, 2007-2012
  • Table 3.1: Pharmaceutical Wholesale and Distribution: World Market Forecast ($bn), AGR (%), CAGR (%), 2015-2026
  • Table 3.2: Pharmaceutical Wholesale and Distribution: Branded Drugs, Generic Drugs and Others, Revenue ($bn) Forecasts, AGR (%), CAGR (%) and Market Shares (%), 2015-2026
  • Table 3.3: Wholesale and Distribution of Branded Drugs: Revenue ($bn) and Market Share (%) Forecast, 2015-2026
  • Table 3.4: Wholesale and Distribution of Generic Drugs: Revenue ($bn) and Market Share (%) Forecast, 2015-2026
  • Table 4.1: Pharma Wholesale & Distribution Leading National Markets: Revenues ($bn) and Market Share (%), 2015
  • Table 4.2: Pharma Wholesale & Distribution Leading National Markets: Revenue ($bn) Forecasts, AGR (%) and CAGR (%), 2015-2026
  • Table 4.3: Revenue ($bn) and Market Share (%) Breakdown of the US Market: The 3 Leading Companies, 2015
  • Table 4.4: US Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2015-2026
  • Table 4.5: Price Controls in Europe, 2015
  • Table 4.6: EU5 Pharma Wholesale & Distribution Market: Revenue ($bn) Forecasts, AGR (%) and CAGR (%), 2015-2026
  • Table 4.7: German Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2015-2026
  • Table 4.8: French Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2015-2026
  • Table 4.9: Italian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2015-2026
  • Table 4.10: Spanish Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2015-2026
  • Table 4.11: UK Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2015-2026
  • Table 4.12: Percentage of the Population Ages 60+ in the US, Europe, Japan, China and India, 2015 and 2030
  • Table 4.13: Japanese Pharmaceutical Wholesale and Distribution Market: Historical Sales ($bn) and Drug Price Revision Growth (%), 2006-2014
  • Table 4.14: Japanese Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2015-2026
  • Table 4.15: Chinese Pharma Wholesale & Distribution: Revenue ($bn) and Market Shares (%) of Leading Companies, 2015
  • Table 4.16: Chinese Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2015-2026
  • Table 4.17: Brazilian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2015-2026
  • Table 4.18: Indian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2015-2026
  • Table 4.19: Russian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2015-2026
  • Table 5.1: Leading Companies in the Pharmaceutical Wholesale and Distribution Market: Revenues ($bn) and Market Shares (%), 2015
  • Table 5.2: Leading Pharmaceutical Wholesale and Distribution Companies: Revenue Forecasts ($bn), AGR (%) and CAGR (%), 2015-2026
  • Table 5.3: Leading Pharmaceutical Wholesale and Distribution Companies: Market Shares (%) for 2015, 2020 and 2026
  • Table 5.4: McKesson, Distribution Solutions: Services and Customers, 2016
  • Table 5.5: McKesson, Technology Solutions: Services and Customers, 2016
  • Table 5.6: McKesson: Historical Revenue ($bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit ($bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2010-2015
  • Table 5.7: McKesson: Revenue ($bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
  • Table 5.8: McKesson: Gross Profit ($bn), Gross Profit Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
  • Table 5.9: Acquisitions by McKesson, 2007-2016
  • Table 5.10: McKesson: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2015-2026
  • Table 5.11: Cardinal Health: Historical Revenue ($bn), Revenue AGR (%), Revenue CAGR (%), Operating Earnings ($bn), AGR (%) and CAGR (%), 2010-2015
  • Table 5.12: Cardinal Health: Revenue ($bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
  • Table 5.13: Cardinal Health: Operating Earnings ($bn) and Annual Growth (%) Breakdown by Business Segment, 2014-2015
  • Table 5.14: Cardinal Health: Revenue ($bn) and Revenue Share (%) Breakdown by Customer, 2015
  • Table 5.15: Selected Acquisitions by Cardinal Health and their Line of Business, 2007-2016
  • Table 5.16: Cardinal Health: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2015-2026
  • Table 5.17: AmerisourceBergen: Historical Revenue ($bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit ($bn), Gross Profit AGR (%) and Gross Profit CAGR (%) 2011-2015
  • Table 5.18: AmerisourceBergen: Revenue ($bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
  • Table 5.19: AmerisourceBergen: Gross Profit ($bn), Gross Profit Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
  • Table 5.20: AmerisourceBergen: Revenue ($bn) and Revenue Share (%) Breakdown by Customer, 2015
  • Table 5.21: Acquisitions by AmerisourceBergen and their Line of Business, 2007-2016
  • Table 5.22: AmerisourceBergen: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2015-2026
  • Table 5.23: Walgreens Boots Alliance: Revenue ($bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit ($bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2015
  • Table 5.24: Walgreens Boots Alliance: Revenue ($bn), AGR (%), and CAGR (%) Forecast, 2015-2026
  • Table 5.25: MEDIPAL Holdings: Consolidated Subsidiary Companies, 2016
  • Table 5.26: MEDIPAL Holdings: Historical Revenue (¥bn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (¥bn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2015
  • Table 5.27: MEDIPAL Holdings: Revenue (¥bn, $bn) and Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
  • Table 5.28: MEDIPAL Holdings: Operating Income ($bn, ¥bn), Operating Income Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
  • Table 5.29: MEDIPAL Holdings: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2015-2026
  • Table 5.30: PHOENIX Group: Subsidiary Companies, 2015
  • Table 5.31: PHOENIX Group: Historical Revenue (€bn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (€bn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2015
  • Table 5.32: PHOENIX Group: Revenue (€bn, $bn), Revenue Share (%) Breakdown by Region, 2014
  • Table 5.33: PHOENIX Group: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2015-2026
  • Table 5.34: SINOPHARM Group: Historical Revenue (RMBbn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (RMBbn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2015
  • Table 5.35: SINOPHARM Group: Revenue (RMBbn, $bn) and Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
  • Table 5.36: SINOPHARM Group: Operating Profit (RMBbn, $bn), Operating Profit Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
  • Table 5.37: SINOPHARM Group: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2015-2026
  • Table 5.38: Alfresa Holdings: List of Significant Subsidiaries and Affiliates, 2015
  • Table 5.39: Alfresa Holdings: Historical Revenue (¥bn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (¥bn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2015
  • Table 5.40: Alfresa Holdings: Sales Launches in the Manufacturing Business Segment, 2013-2014
  • Table 5.41: Alfresa Holdings: Revenue (¥bn, $bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
  • Table 5.42: Alfresa Holdings: Gross Profit (¥bn, $bn), Gross Profit Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
  • Table 5.43: Alfresa Holdings: Targets of the 13-15 Medium-term Management Plan - The Challenge of Reform- Uniting to Climb New Peaks, 2015
  • Table 5.44: Alfresa Holdings: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2015-2026
  • Table 5.45: SUZUKEN: Historical Revenue (¥bn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (¥bn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2015
  • Table 5.46: SUZUKEN: Revenue (¥bn, $bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
  • Table 5.47: SUZUKEN: Operating Income (¥bn, $bn), Operating Income Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
  • Table 5.48: SUZUKEN: Revenue (¥bn, $bn), Revenue Share (%) Breakdown for Pharmaceuticals Distribution Segment by Region, 2014
  • Table 5.49: SUZUKEN: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2015-2026
  • Table 5.50: Shanghai Pharmaceuticals Holding: Historical Revenue (RMBbn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (RMBbn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2015
  • Table 5.51: Shanghai Pharmaceuticals Holding: Revenue (RMBbn, $bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
  • Table 5.52: Shanghai Pharmaceuticals Holding: Operating Profit (RMBbn, $bn), Operating Profit Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
  • Table 5.53: Shanghai Pharmaceuticals Holding: Distribution Revenue (RMBbn, $bn), Distribution Revenue Share (%) Breakdown by Region, 2015
  • Table 5.54: Shanghai Pharmaceuticals Holding: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2015-2026
  • Table 6.1: The Pharmaceutical W&D Market: Strengths and Weaknesses, 2016
  • Table 6.2: The Pharmaceutical W&D Market: Opportunities and Threats, 2015-2026
  • Table 6.3: Strengths and Weaknesses of the DTP Distribution Model, 2015
  • Table 6.4: ITR Ratings and Corresponding Reimbursement Rates, 2015
  • Table 6.5: Social, Technological, Economic and Political Factors Influencing the Pharmaceutical Wholesale and Distribution Market (STEP Analysis), 2015-2026

List of Figures

  • Figure 1.1: Forecast Global Population Over the Age of 65 Years (millions), Annual Growth Rate (%), 2015-2026
  • Figure 1.2: Routes of Drug Distribution, 2016
  • Figure 2.1: Routes of Drug Distribution, 2016
  • Figure 3.1: The Global Pharmaceutical Wholesale and Distribution Market: Drivers and Restraints, 2016
  • Figure 3.2: Pharmaceutical Wholesale and Distribution: World Market Forecast ($bn), 2015-2026
  • Figure 3.3: Branded Drugs, Generic Drugs and Others: Market Shares (%), 2015
  • Figure 3.4: Branded Drugs, Generic Drugs and Others: Market Shares (%), 2020
  • Figure 3.5: Branded Drugs, Generic Drugs and Others: Market Shares (%), 2026
  • Figure 3.6: Wholesale and Distribution of Branded Drugs, Generic Drugs and Others: Revenue Forecasts ($bn), 2015-2026
  • Figure 3.7: Wholesale and Distribution of Branded Drugs: Revenue ($bn) Forecast, 2015-2026
  • Figure 3.8: Wholesale and Distribution of Generic Drugs: Revenue ($bn) Forecast, 2015-2026
  • Figure 4.1: Pharma Wholesale & Distribution Leading National Markets: Shares (%), 2015
  • Figure 4.2: Pharma Wholesale & Distribution Leading National Markets: Shares (%), 2020
  • Figure 4.3: Pharma Wholesale & Distribution Leading National Markets: Shares (%), 2026
  • Figure 4.4: Market Share (%) Breakdown of the US Market: The 3 Leading Companies, 2015
  • Figure 4.5: US Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2015-2026
  • Figure 4.6: US Pharma Wholesale & Distribution Market: Drivers and Restraints, 2016-2026
  • Figure 4.7: EU5 Pharma Wholesale & Distribution Market Shares (%), 2015, 2020 and 2026
  • Figure 4.8: EU5 Pharma Wholesale & Distribution Market: Revenue ($bn) Forecasts, 2015-2026
  • Figure 4.9: EU Pharma Wholesale & Distribution Market: Drivers and Restraints, 2016
  • Figure 4.10: German Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2015-2026
  • Figure 4.11: German Pharma Wholesale & Distribution Market: Drivers and Restraints, 2016
  • Figure 4.12: French Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2015-2026
  • Figure 4.13: French Pharma Wholesale & Distribution Market: Drivers and Restraints, 2016
  • Figure 4.14: Italian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2015-2026
  • Figure 4.15: Italian Pharma Wholesale & Distribution Market: Drivers and Restraints, 2016
  • Figure 4.16: Spanish Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2015-2026
  • Figure 4.17: Spanish Pharma Wholesale & Distribution Market: Drivers and Restraints, 2016
  • Figure 4.18: UK Pharma Wholesale & Distribution Market: Revenue ($bn), 2015-2026
  • Figure 4.19: UK Pharma Wholesale & Distribution Market: Drivers and Restraints, 2016
  • Figure 4.20: Percentage of the Population Ages 65+ in the US, Europe, Japan, China and India, 2015 and 2030
  • Figure 4.21: Japanese Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2015-2026
  • Figure 4.22: Japanese Pharma Wholesale & Distribution Market: Drivers and Restraints, 2016
  • Figure 4.23: Chinese Pharma Wholesale & Distribution: Market Shares (%) of Leading Companies, 2015
  • Figure 4.24: Chinese Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2015-2026
  • Figure 4.25: Chinese Pharma Wholesale & Distribution Market: Drivers and Restraints, 2016
  • Figure 4.26: Brazilian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2015-2026
  • Figure 4.27: Brazilian Pharma Wholesale & Distribution Market: Drivers and Restraints, 2016
  • Figure 4.28: Pharma Wholesale & Distribution Model in India, 2016
  • Figure 4.29: Indian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2015-2026
  • Figure 4.30: Indian Pharma Wholesale & Distribution Market: Drivers and Restraints, 2016
  • Figure 4.31: Russian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2015-2026
  • Figure 4.32: Russian Pharma Wholesale & Distribution Market: Drivers and Restraints, 2016
  • Figure 5.1: Leading Pharmaceutical Wholesale and Distribution Companies: Market Shares (%), 2015
  • Figure 5.2: Leading Pharmaceutical Wholesale and Distribution Companies: Market Shares (%), 2020
  • Figure 5.3: Leading Pharmaceutical Wholesale and Distribution Companies: Market Shares (%), 2026
  • Figure 5.4: Leading Pharmaceutical W&D Companies: Drivers and Restraints, 2016
  • Figure 5.5: McKesson: Historical Revenue ($bn), Revenue AGR (%), Gross Profit ($bn) and Gross Profit AGR (%), 2010-2015
  • Figure 5.6: McKesson: Revenue Share (%) Breakdown by Business Segment, 2015
  • Figure 5.7: McKesson: Gross Profit Share (%) Breakdown by Business Segment, 2015
  • Figure 5.8: McKesson: Revenue ($bn) Forecast, 2015-2026
  • Figure 5.9: McKesson: Drivers and Restraints, 2016-2026
  • Figure 5.10: Cardinal Health: Historical Revenue ($bn), Revenue AGR (%), Operating Earnings ($bn) and Operating Earnings AGR (%), 2010-2015
  • Figure 5.11: Cardinal Health: Revenue Share (%) Breakdown by Business Segment, 2015
  • Figure 5.12: Cardinal Health: Revenue Share (%) Breakdown by Customer, 2015
  • Figure 5.13: Cardinal Health: Revenue ($bn) Forecast, 2015-2026
  • Figure 5.14: Cardinal Health: Drivers and Restraints, 2015-2026
  • Figure 5.15: AmerisourceBergen: Historical Revenue ($bn), Revenue AGR (%), Gross Profit ($bn) and Gross Profit AGR (%), 2011-2015
  • Figure 5.16: AmerisourceBergen: Revenue Share (%) Breakdown by Business Segment, 2015
  • Figure 5.17: AmerisourceBergen: Revenue ($bn) Breakdown by Customer, 2015
  • Figure 5.18: AmerisourceBergen: Revenue ($bn) Forecast, 2015-2026
  • Figure 5.19: AmerisourceBergen: Drivers and Restraints, 2015-2026
  • Figure 5.20: Walgreens Boots Alliance: Revenue ($bn), Revenue AGR (%), Gross Profit ($bn) and Gross Profit AGR (%), 2011-2015
  • Figure 5.21: Walgreens Boots Alliance: Revenue ($bn) Forecast, 2015-2026
  • Figure 5.22: Alliance Boots: Drivers and Restraints, 2015-2026
  • Figure 5.23: MEDIPAL Holdings: Historical Revenue (¥bn), Revenue AGR (%), Gross Profit (¥bn) and Gross Profit AGR (%), 2011-2015
  • Figure 5.24: MEDIPAL Holdings: Revenue Share (%) Breakdown by Business Segment, 2015
  • Figure 5.25: MEDIPAL Holdings: Operating Income Share (%) Breakdown by Business Segment, 2015
  • Figure 5.26: MEDIPAL Holdings: Revenue ($bn) Forecast, 2015-2026
  • Figure 5.27: MEDIPAL Holdings: Drivers and Restraints, 2015-2026
  • Figure 5.28: PHOENIX Group: Historical Revenue (€bn), Revenue AGR (%), Gross Profit (€bn) and Gross Profit AGR (%), 2011-2015
  • Figure 5.29: PHOENIX Group: Revenue Share (%) Breakdown by Region, 2014
  • Figure 5.30: PHOENIX Group: Revenue ($bn) Forecast, 2015-2026
  • Figure 5.31: PHOENIX Group Drivers and Restraints, 2015-2026
  • Figure 5.32: SINOPHARM Group: Historical Revenue (RMBbn), Revenue AGR (%), Gross Profit (RMBbn) and Gross Profit AGR (%), 2011-2015
  • Figure 5.33: SINOPHARM Group: Revenue ($bn) Forecast, 2015-2026
  • Figure 5.34: SINOPHARM Group: Drivers and Restraints, 2015-2026
  • Figure 5.35: Alfresa Holdings: Historical Revenue (¥bn), Revenue AGR (%), Gross Profit (¥bn), Gross Profit AGR (%), 2011-2015
  • Figure 5.36: Alfresa Holdings: Revenue Share (%) Breakdown by Business Segment, 2015
  • Figure 5.37: Alfresa Holdings: Gross Profit Share (%) Breakdown by Business Segment, 2015
  • Figure 5.38: Alfresa Holdings: Revenue ($bn) Forecast, 2015-2026
  • Figure 5.39: Alfresa Holdings: Drivers and Restraints, 2015-2026
  • Figure 5.40: SUZUKEN: Historical Revenue (¥bn), Revenue AGR (%), Gross Profit (¥bn) and Gross Profit AGR (%), 2011-2015
  • Figure 5.41: SUZUKEN: Revenue Share (%) Breakdown by Business Segment, 2015
  • Figure 5.42: SUZUKEN: Operating Income Share (%) Breakdown by Business Segment, 2015
  • Figure 5.43: SUZUKEN: Revenue Share (%) Breakdown by Region in Japan, 2014
  • Figure 5.44: SUZUKEN: Revenue ($bn) Forecast, 2015-2026
  • Figure 5.45: SUZUKEN: Drivers and Restraints, 2016-2026
  • Figure 5.46: Shanghai Pharmaceuticals Holding: Historical Revenue (RMBbn), Revenue AGR (%), Gross Profit (RMBbn) and Gross Profit AGR (%), 2011-2015
  • Figure 5.47: Shanghai Pharmaceuticals Holding: Revenue Share (%) Breakdown by Business Segment, 2015
  • Figure 5.48: Shanghai Pharmaceuticals Holding: Revenue Share (%) Breakdown by Region, 2015
  • Figure 5.49: Shanghai Pharmaceuticals Holding: Revenue ($bn) Forecast, 2015-2026
  • Figure 5.50: Shanghai Pharmaceuticals Holding: Drivers and Restraints, 2015-2026
  • Figure 6.1: Comparison of the Wholesale and DTP Routes of Distribution, 2016
  • Figure 6.2: Drug Pedigree Legislation: EU vs. US, 2015
  • Figure 8.1: Pharmaceutical Wholesale and Distribution: Global Market Forecasts ($bn) by Submarket, 2015-2026
  • Figure 8.2: Leading National Pharmaceutical Wholesale and Distribution Markets: Revenue Projections ($bn), 2015, 2020 and 2026
  • Figure 8.3: Leading Pharmaceutical Wholesale and Distribution Companies: Revenue ($bn) Projections 2015, 2020 and 2026

Companies Listed

  • 36.6 Group
  • AAH Pharmaceuticals
  • AccessClosure
  • ACM (Authority for Consumers & Markets)
  • ADG Apotheken-Dienstleistungsgesellschaft mbH
  • Admenta Italia
  • Alfresa Corporation
  • Alfresa Healthcare Corporation
  • Alfresa Holdings
  • Alfresa Medical Service Corporation
  • Alfresa Nikken Sangyo Corporation
  • Alfresa Pharma Corporation
  • Alfresa System Corporation
  • Alliance Boots
  • Alliance Healthcare
  • Alphega Network
  • AmerisourceBergen
  • Apokjeden AS
  • Apollo Medical Holdings
  • ARATA CORPORATION
  • Asociación Cooperativas Farmacéuticas (Acofarma)
  • AssuraMed
  • ASTIS Co.
  • AstraZeneca
  • Athos Farma
  • Barr Pharmaceuticals
  • Bayer
  • Biologics Inc
  • Bristol-Myers Squibb
  • Brocacef Groep NV
  • Bundesverband des PharmazeutischenGrosshandel (PHAGRO)
  • Cardinal Foods
  • Cardinal Health
  • Cardinal Health China
  • CareFusion
  • Catalent Pharma Solutions
  • Celesio AG
  • Celesio UK
  • CERP BretagneNord
  • CERP Network
  • CERP Rouen
  • China Health Systems
  • China National Pharmaceutical Group
  • Chuo Unyu Co.
  • Cofares
  • Comifar
  • Comifar Group
  • Cordis
  • CS YAKUHIN CO.
  • CVS Caremark
  • Daiichi Sankyo Propharma Co
  • DEA
  • Dong Ying (Jiangsu) Pharmaceuticals Co.
  • DrogariasTamoio Network
  • Drug Trading Company
  • Emart Company
  • ERP Rhin Rhone Mediterranee
  • European Association of Euro-Pharmaceutical Companies (EAEPC)
  • European Court of Justice
  • European Pharmacy Network (EPN)
  • Express Scripts
  • Food and Drug Administration (US FDA)
  • Gilead Sciences
  • GlaxoSmithKline (GSK)
  • Guangzhou Pharmaceutical Company
  • Guangzhou Pharmaceuticals Corporation (GP Corp)
  • Hanshin Dispensing Pharmacy Holdings Co.
  • Harvard Drug
  • Healthcare Solutions Holding
  • Hefame
  • Institute for Pharmaeconomic Research (IPF)
  • Japanese Pharmaceutical Wholesalers Association
  • Johnson & Johnson
  • Katz Group
  • Kenzmedico Co.
  • Kinray
  • Kowa Pharmaceuticals Co.
  • Libra AG
  • Life Medicom Co.
  • LloydsPharmacy
  • McKesson
  • McQueary Brothers of Springfield
  • Medicaid
  • Medicare
  • Medicine Shoppe Canada
  • Medipal Holdings
  • Mediq Apotheken Nederland B.V.
  • Meisho Co.
  • Metro Medical Supply
  • MSD
  • Nakano Yakuhin Co.
  • National Development and Reform Commission (NDRC)
  • National Health Insurance (NHI)
  • National Health Service (NHS)
  • National Pharmaceutical Pricing Authority (NPPA)
  • NaviHealth
  • Nihon Apoch Co
  • Nomeco
  • Novation LLC
  • Novodata Zrt
  • Odashima Limited
  • Oncology Therapeutics
  • Oncoprod
  • Outcomes Incorporated
  • P.JD. Network
  • Panpharma
  • Pfercos Co.
  • Pfizer
  • PharMEDium Healthcare Holdings
  • PHOENIX Arzneiwarengroßhandlung Ges.m.b.H.
  • PHOENIX Farmacija d.d.
  • PHOENIX Group
  • PHOENIX Lékárenský velkoobchod, a.s.
  • PHOENIX Pharma d.o.o.
  • PHOENIX Pharma DOOEL
  • PHOENIX Pharma Polska Sp. z o.o.
  • PHOENIX Pharma S.A.S
  • PHOENIX Pharma Zrt.
  • PHOENIX Pharmahandel
  • PHOENIX Zdravotnícke zásobovanie
  • Polish Pharmaceutical Council (NRA)
  • Polska Grupa Farmaceutyczna, Torfarm
  • Premium Purchasing Partners LP
  • Profarma
  • Prosper
  • Protek
  • PSS World Medical
  • QINGDAO NESCO MEDICAL CO.
  • Raintree Oncology Services
  • Ratiopharm
  • Red Oak
  • Rexall Health
  • RYUYAKU CO.
  • S.D.Next Co.
  • Sanacorp
  • Sandoz
  • Sanki Clinical Link Co.
  • Sanki Corporation
  • Sanki MediHeart Limited
  • Sanki Wellbe Co., Ltd. S-Care Mate Co.
  • Sanofi
  • Sanwa Kagaku Kenkyusho Co.
  • Sciclone Trade
  • SEIWA SANGYO CO.
  • Shanghai Pharmaceuticals
  • Shikoku Alfresa Corporation
  • Shinsegai Group
  • Shoyaku Co.
  • SIA International
  • SIA Tamro
  • SINOPHARM Group Co.
  • Sonexus Health
  • St. Francis Group
  • State Food and Drug Administration (SFDA)
  • SUNPHARMA
  • SUZUKEN
  • Suzuken Iwate Co.
  • Suzuken Okinawa Yakuhin Co.
  • TAMPEI NAKATA CO.
  • Tamro AB
  • Tamro Eesti OÜ
  • Tamro Oyj
  • The Healthcare Distribution Management Association (HDMA)
  • Tokiwa Yakuhin Co
  • Tradex International
  • UAB Tamro
  • US Oncology Holdings
  • Vantage Oncology
  • Walgreens
  • Walmart
  • World Courier Group
  • Wuhan Chopper Biology
  • Zuellig Pharma China
Back to Top